Parkman Healthcare Partners’s Eton Pharmaceutcials ETON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-276,890
Closed -$3.69M 96
2024
Q4
$3.69M Buy
276,890
+16,664
+6% +$169K 0.49% 55
2024
Q3
$1.56M Buy
260,226
+7,029
+3% +$29.7K 0.2% 81
2024
Q2
$833K Buy
253,197
+54,029
+27% +$189K 0.11% 82
2024
Q1
$747K Hold
199,168
0.09% 96
2023
Q4
$872K Buy
199,168
+34,168
+21% +$137K 0.12% 82
2023
Q3
$688K Buy
+165,000
New +$637K 0.13% 97

Other funds holding ETON

Parkman Healthcare Partners's ETON Position: Q1 2025 in Review

Parkman Healthcare Partners sold out of Eton Pharmaceutcials (ETON) in Q1 2025, closing a stake of 276,890 shares — an estimated $3.69M sold.

Parkman Healthcare Partners first reported a position in ETON in Q3 2023 and held it in 6 quarters. The position peaked at $3.69M in Q4 2024. 86 funds tracked by Wall St. Rank hold ETON as of Q1 2025.

  • Parkman Healthcare Partners reported no remaining Eton Pharmaceutcials position as of Q1 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 276,890 Eton Pharmaceutcials shares in Q1 2025, an estimated $3.69M.
  • Parkman Healthcare Partners first reported a position in Eton Pharmaceutcials in Q3 2023 and held it in 6 quarters.
  • Parkman Healthcare Partners's Eton Pharmaceutcials position peaked at $3.69M in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2025.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.